Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
50-33-9
Molecular formula
C19H20N2O2
Molecular weight
308.3743 g/mol
Drug class
Non-steroidal anti-inflammatory drug (NSAID)pyrazolidinedione derivative
Mechanism of action
Inhibits cyclo-oxygenase-mediated prostaglandin synthesis, reducing inflammatory mediators and producing anti-inflammatory, analgesic and antipyretic effects. This is a class-level pharmacological description; exact clinical use is restricted by species and product authorisation.
Indications / reported uses
Veterinary use: relief of inflammatory conditions associated with the musculoskeletal system in dogs and horses under applicable veterinary authorisations. Certain equine oral formulations are not for use in horses intended for human consumption. It is not a general human therapeutic indication.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Phenylbutazone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Phenylbutazone Permitted Daily Exposure (PDE) report (the Phenylbutazone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Phenylbutazone Occupational Exposure Limit (OEL) report (the Phenylbutazone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.